

CIVIL, R., DOLAN, E., SWINTON, P.A., SANTOS, L., VARLEY, I., ATHERTON, P.J., ELLIOTT-SALE, K.J. and SALE, C. [2023]. P1NP and β -CTX-1 responses to a prolonged, continuous running bout in young healthy adult males: a systematic review with individual participant data meta-analysis. *Sports medicine-open* [online], (accepted).

P1NP and β -CTX-1 responses to a prolonged, continuous running bout in young healthy adult males: a systematic review with individual participant data meta-analysis.

CIVIL, R., DOLAN, E., SWINTON, P.A., SANTOS, L., VARLEY, I., ATHERTON, P.J., ELLIOTT-SALE, K.J. and SALE, C.

2023

The version of record of this article, first published in Sports Medicine - Open, is available online at Publisher's website: [https://doi.org/\[insert DOI\]](https://doi.org/[insert DOI]).

1 **P1NP AND β -CTX-1 RESPONSES TO A PROLONGED, CONTINUOUS RUNNING**
2 **BOUT IN YOUNG HEALTHY ADULT MALES: A SYSTEMATIC REVIEW WITH**
3 **INDIVIDUAL PARTICIPANT DATA META-ANALYSIS**

4 Rita Civil^{*1,2}, Eimear Dolan³, Paul A. Swinton⁴, Livia Santos², Ian Varley², Philip J.
5 Atherton⁵, Kirsty J. Elliott-Sale^{2,6}, Craig Sale^{2,6}

6

7

8 ¹ School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.

9 ² Musculoskeletal Physiology Research Group, Sport, Health and Performance Enhancement (SHAPE)

10 Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK.

11 ³ Applied Physiology & Nutrition Research Group; School of Physical Education and Sport; Rheumatology

12 Division; Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.

13 ⁴ School of Health Sciences, Robert Gordon University, Aberdeen, UK.

14 ⁵ Centre of Metabolism, Ageing & Physiology (CMAP), MRC-Versus Arthritis Centre of Excellence for

15 Musculoskeletal Ageing Research, Nottingham NIHR Biomedical Research Centre, School of Medicine,

16 University of Nottingham, Derby, UK.

17 ⁶ Department of Sport and Exercise Sciences, Institute of Sport, Manchester Metropolitan University,

18 Manchester, UK.

19

20

21

22 *Corresponding author:

23 Professor Craig Sale, Institute of Sport, Manchester Metropolitan University, 99 Oxford Road,

24 Manchester, M1 7EL. Email: c.sale@mmu.ac.uk.

25 Abstract

26 BACKGROUND: Circulating biomarkers of bone formation and resorption are widely used in exercise
27 metabolism research, but their responses to exercise are not clear. PURPOSE: To quantify group
28 responses and inter-individual variability of P1NP and β -CTX-1 after prolonged, continuous running
29 (60-120 min at 65-75% VO₂max) in young healthy adult males using individual participant data (IPD)
30 meta-analysis. METHODS: The protocol was designed following PRISMA-IPD guidelines. Changes
31 in P1NP and β -CTX-1 relative to baseline were measured during, immediately after, and in the hours
32 and days following exercise. Typical hourly and daily variations were estimated from P1NP and β -
33 CTX-1 changes relative to baseline in non-exercise (control) conditions. Group responses and inter-
34 individual variability were quantified with estimates of the mean and standard deviation of the
35 difference, and the proportion of participants exhibiting an increased response. Models were conducted
36 within a Bayesian framework with random intercepts to account for systematic variation across studies.
37 RESULTS: P1NP levels increased during and immediately after running, where the proportion of
38 response was close to 100% (75% CrI: 99 to 100%). P1NP levels returned to baseline levels within 1
39 hour and over the next 4 days, showing comparable mean and standard deviation of the difference with
40 typical hourly ($0.1 \pm 7.6 \text{ ng}\cdot\text{ml}^{-1}$) and daily ($-0.4 \pm 5.7 \text{ ng}\cdot\text{ml}^{-1}$) variation values. β -CTX-1 levels
41 decreased during and up to 4 hours after running with distributions comparable to typical hourly
42 variation ($-0.13 \pm 0.11 \text{ ng}\cdot\text{ml}^{-1}$). There was no evidence of changes in β -CTX-1 levels during the 4 days
43 after the running bout, where distributions were also similar between the running data and typical daily
44 variation and ($-0.03 \pm 0.10 \text{ ng}\cdot\text{ml}^{-1}$). CONCLUSION: Transient increases in P1NP were likely
45 biological artefacts (*e.g.*, connective tissue leakage) and not reflective of bone formation. Comparable
46 small decreases in β -CTX-1 identified in both control and running data, suggested that these changes
47 were due to the markers' circadian rhythm and not the running intervention. Hence, prolonged
48 continuous treadmill running did not elicit bone responses, as determined by P1NP and β -CTX-1, in
49 this population. REGISTRATION: The protocol for this review was pre-registered on the Open Science
50 Framework prior to implementation (<https://osf.io/y69nd>).

51

52 **Key words:** bone remodelling, bone markers, exercise, running, inter-individual variability, proportion
53 of response.

54 **Key points:**

- 55 • It is unclear whether a single running bout produces bone adaptations, but these potential
56 responses were not captured by bone (re)modelling markers P1NP and β -CTX-1.
- 57 • There is a need for studies that investigate the acute responses of bone (re)modelling markers
58 to different types of exercise interventions and across different populations, which include a
59 control (non-exercise) group.

60

61 **Abbreviations**

62	BMD	Bone mineral density
63	CLIA	Chemiluminescence immunoassay
64	CrI	Credible intervals
65	DXA	Dual-energy X-ray absorptiometry
66	ECLIA	Electro-chemiluminescence assay
67	ELISA	Enzyme-linked immunosorbent assay
68	IPD	Individual participant data
69	P1NP	N-terminal propeptide of type 1 procollagen
70	PICOS	Population, Intervention, Comparator, Outcomes and Study Design
71	pQCT	Peripheral quantitative computed tomography
72	PRISMA	Preferred Reporting Items for Systematic Review and Meta-Analysis
73	PTH	Parathyroid hormone
74	RIA	Radioimmunoassay
75	SD	Standard deviation
76	VO _{2max}	Maximum rate of oxygen consumption
77	β -CTX-1	C-terminal telopeptide of type 1 collagen

78

79 1. Introduction

80 Weight-bearing exercise is generally considered to be beneficial for bone health and is associated with
81 long-term (*i.e.*, months, years) improvements in bone mineral density (BMD) and bone architecture,
82 particularly at load bearing sites [1, 2, 3, 4]. Although the best exercise regimen (*i.e.*, type, intensity,
83 duration, and frequency) to optimise bone responses is still not well defined, research suggests that
84 dynamic, high-impact, rapid, multi-directional movement patterns and unaccustomed loads, with a
85 sufficient load intensity, are likely to produce the largest osteogenic stimulus [5, 6, 7, 8]. The effects of
86 endurance running exercise on bone are interesting because, although running produces greater
87 gravitational loading compared to other low-impact activities, such as cycling [9], it also has a repetitive
88 loading cycle and has been associated with a relatively high prevalence of stress fracture injury [10,
89 11]. Low BMD is prevalent in endurance runners, particularly at non-loaded sites [12], and it seems
90 that beneficial effects of mechanical loading may not counteract the potential negative influences
91 associated with endurance exercise [11], such as micro-damage accumulation and low energy
92 availability [13].

93

94 Examining the dynamic bone response to acute running exercise bouts is a logical approach to further
95 investigate the effects of this exercise type on bone, which can be done by measuring changes in bone
96 (re)modelling markers, measured in blood, before and after a running intervention. Almost all studies
97 that have included these measurements, however, were not designed to directly answer this question
98 and did not include a control (non-exercise) group, which makes it difficult to separate running-induced
99 responses from circadian variation [14]. Furthermore, the results from the few studies that have included
100 a running intervention and a control group are inconsistent. Two studies reported no significant
101 differences in bone formation marker P1NP levels 1-24h hours after an intermittent [15] or a continuous
102 [16] bout of running compared to a non-exercise control condition, but Alkahtani *et al.* [17] reported
103 increases in P1NP immediately and 24h after intermittent running. In terms of bone resorption,
104 increases in β -CTX-1 have been shown 1h, but not 24h, after intermittent running [15] and 24-96h after
105 continuous running [16]. Potential explanations for these discrepant results include differences in

106 exercise regimen (*i.e.*, duration, intensity, intermittent/continuous) and measurement error (*i.e.*,
107 instrumentation and biological noise), and lack of standardisation of factors such as sleep, diet, physical
108 activity prior and following the running bout. It is also possible that different individuals respond
109 differently to the exercise intervention itself (inter-individual variability).

110

111 The extent of inter-individual variation in the bone biomarker response to prolonged continuous running
112 is unknown. The estimation of the typical variation in observed scores derived from measurement or
113 biological noise can be quantified through the variation in scores in control conditions (by including a
114 control group) [18]. For example, when investigating the responses of bone (re)modelling markers to
115 an exercise intervention, the estimation of typical variation would allow quantification of the degree to
116 which the observed changes were affected by factors external to the intervention itself, such as circadian
117 rhythms; and, therefore, would allow quantification of the degree to which the intervention itself may
118 contribute toward the observed variation. Whilst obtaining accurate estimates of these variability
119 assessments is difficult for single studies, individual participant data (IPD) meta-analytic approaches
120 provide better estimates of mean responses with bigger sample sizes and allow for the assessment of
121 effects at the participant level by using the raw data from selected studies [19, 20], and, thus, can
122 determine inter-individual variability.

123

124 To better understand bone responses to acute bouts of running, the aims of this study were to (i) evaluate
125 the mean responses of P1NP and β -CTX-1 to a prolonged, continuous running exercise bout in young
126 healthy adult males, (ii) estimate the inter-individual variability in bone (re)modelling marker
127 responses, and (iii) determine to what degree any inter-individual variability was associated with the
128 prolonged, continuous running bout itself (herein termed the intervention response), versus those related
129 to external factors such as circadian variation.

130

131

132

133 **2. Methods**

134 The protocol for this review included all items described in the checklist of Preferred Reporting Items
135 for Systematic Review and Meta-Analysis of Individual Participant Data (PRISMA-IPD) [20, 21]. The
136 protocol for this review was pre-registered on the Open Science Framework prior to implementation
137 (<https://osf.io/y69nd>).

138

139 **2.1. Updates from the pre-registered protocol**

140 In the pre-registered protocol, a combined approach of aggregate data and individual participant data
141 meta-analyses was proposed. Because individual participant data were obtained from all running
142 studies, however, the aggregate analysis was deemed unnecessary for the purpose of this investigation.
143 The pre-registered protocol indicated that the statistical model would include the estimation of
144 variability ratio (ratio of standard deviation of inter-individual difference scores relative to measurement
145 error values); this estimation was not included in the statistical approach due to the fact that
146 measurement error values were often as large as variation in the intervention.

147

148 **2.2. Eligibility Criteria**

149 The PICOS (Population, Intervention, Comparator, Outcomes and Study Design) approach was used to
150 guide the determination of eligibility criteria for this study.

151

152 *2.2.1. Population*

153 Studies that included young (18-35 years old), healthy (*i.e.*, non-smokers, injury free and not taking
154 medication from any condition known to affect bone metabolism), active males ($VO_{2max} \sim 50 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$)
155 were considered for inclusion. Differences in training status are unlikely to influence the
156 responses of bone (re)modelling markers after a running exercise bout [16] and, therefore, participants
157 included young healthy males who were active (*i.e.*, recreationally) or endurance trained (*e.g.*, runners,
158 triathletes). Only male participants were included because most studies in this area have focused upon

159 young, healthy, adult male populations. Studies in healthy active females are lacking on this topic, a
160 disparity that is considered in the discussion.

161

162 2.2.2. *Intervention*

163 The term ‘intervention’ was taken to mean a prolonged, continuous running bout, regardless of whether
164 or not this was the focus of the original studies from which the data were extracted. Studies were
165 considered for inclusion if they included blood sample collections at baseline, before, during, and after
166 prolonged, continuous treadmill running at an intensity of $\geq 65\%$ VO_{2max} and with a duration of 60-120
167 min. In order to reduce variation due to circadian rhythms [14, 22] and feeding [23, 24, 25], studies
168 were only included if they were conducted in the morning with a baseline sample collected after an
169 overnight fast and the rest of the samples collected in a fasted state or consuming a non-caloric placebo.
170 Studies were only included in this review if they involved a continuous treadmill running-based exercise
171 bout to control for mechanical loading across studies.

172

173 2.2.3. *Comparator*

174 Bone (re)modelling marker responses to running were measured by comparing changes in markers
175 during and post-running (*i.e.*, from blood samples taken during and in the hours and days after the
176 running bout) relative to the baseline sample.

177

178 To quantify typical variation data from control conditions (resting/non-exercise) were required,
179 however, most of the selected running studies did not include a non-exercise control group, which
180 limited the available data to quantify the typical variation of these markers in resting conditions. For
181 this reason, studies that did not fulfil the exercise intervention criteria but fulfilled the rest of the
182 inclusion criteria (*e.g.*, population, outcomes) and included a control/non-exercise group (with fasted
183 samples collected during the hours and days after baseline) were also used to quantify typical variation.

184

185 2.2.4. *Outcomes and Prioritisation*

186 P1NP and β -CTX-1 were the primary outcomes of interest for this study as these are the reference
187 markers for bone formation and resorption [26].

188

189 **2.3. Study design**

190 Any experimental study design that reported the relevant data pre and post a prolonged, continuous
191 running bout or at rest was considered for inclusion, including crossover or parallel group, controlled
192 or uncontrolled, and randomised or non-randomised trials.

193

194 **2.4. Search strategy and study selection**

195 Studies were identified directly from the list of included articles in a recent systematic review and meta-
196 analysis on the bone (re)modelling marker response to acute exercise interventions [27, 28]. For further
197 details of the protocol, including eligibility criteria, search strategy, study selection and data extraction,
198 of this meta-analysis please refer to Dolan *et al.*, [27]. In summary, seven electronic databases were
199 used to source the material: MEDLINE, Embase, Cochrane CENTRAL, Sport Discus, PEDro,
200 LILACS, and IBEC; and were supplemented by citation screening of all selected studies and relevant
201 reviews and book chapters. This search was last updated in May 2022. Additionally, data from a study
202 included in a PhD thesis from the university's research group that fulfilled the inclusion criteria was
203 included [29].

204

205 The list of articles selected for inclusion in the investigation by Dolan *et al.* [28], was subsequently
206 screened to identify studies that met the eligibility criteria for the current study. The search strategy and
207 study selection process are illustrated using a modified version of the PRISMA-IPD search flow
208 diagram (**Figure 1**).

209
210
211
212
213
214
215
216
217
218
219




Figure 1. Selection of studies flow diagram. Studies including running data (grey) and studies including control data (white).

220
221

222 2.5. Data extraction and items

223 Data from selected studies were first extracted into a custom and pre-piloted spreadsheet
224 (**Supplementary file 1**) including: study details (authors; year; study design); participant characteristics
225 (final *n*; training status; age; height; weight; BMI); exercise characteristics (duration; intensity; total
226 work [duration*intensity]); sampling conditions (time of day; diet and exercise standardisation/control
227 before, during and after the intervention, sample handling, assay type); and, if appropriate, intervention
228 group (*e.g.*, trained/recreational participants, placebo).

229

230 Anonymised, individual participant raw data were collected from each publication when available (*e.g.*,
231 supplemental material), or directly from study authors, who were contacted via email, with a maximum
232 of two email attempts made over a period of one month. Individual participant data were entered into

233 codebooks (**Supplementary file 1**) and transformed to the same units when included in the codebook
234 (*i.e.*, for P1NP and β -CTX-1 data $\text{ng}\cdot\text{ml}^{-1}$ was used).

235

236 **2.6. Risk of bias assessment in individual studies**

237 The risk of bias for each study was independently assessed in duplicate by two members of the research
238 team using a modified version of the Downs and Black [30] checklist (**Supplementary file 2**). This tool
239 was selected because it provides a comprehensive assessment of the methodological quality of both
240 randomised and non-randomised trials in healthcare research and has been validated as a tool to evaluate
241 the quality of reporting as well as internal and external validity [30]. The modified checklist had a total
242 of 16 items, a maximum score of 20 and was tailored to identify the methodological concerns relevant
243 for this analysis. This tool was not used to exclude any eligible studies.

244

245 **2.7. Statistical analysis and calculations**

246 Individual participant data meta-analyses were conducted to quantify the responses of P1NP and β -
247 CTX-1 for all available time-points during, immediately after, and following exercise. Responses were
248 quantified based upon estimates of the mean difference (by subtracting each time-point from baseline),
249 the standard deviation (SD) of the difference, and the proportion of participants exhibiting an increased
250 response. All models were conducted within a Bayesian framework with random intercepts to account
251 for systematic variation across individual studies. Change scores relative to baseline were calculated
252 for each participant on an absolute scale ($\text{ng}\cdot\text{mL}^{-1}$) with distributional models used to estimate both the
253 mean difference and standard deviation of the difference. Visual exploration of the data identified the
254 existence of heteroscedasticity, with a positive relationship between baseline values and residuals from
255 change scores. Therefore, the baseline value was entered as a predictor of the standard deviation of the
256 difference. Default priors were used for all parameters, including weakly informative Student-t and half
257 Student-t distributions with 3 degrees of freedom for location and variance parameters.

258

259 Where estimates showed a mean difference and greater standard deviation of change scores for the
260 exercise group, proportion of positive response was estimated by calculating the amount of the
261 distribution (mean difference plus additional standard deviation of the difference) above zero.
262 Inferences from all analyses were performed on posterior samples generated using the Hamiltonian
263 Markov Chain Monte Carlo method (five chains, 100,000 iterations and 50,000 warmup).
264 Interpretations were based on the median value (0.5-quantile), credible intervals (CrIs) and subjective
265 probabilities calculated from the proportion of the posterior sample that exceeded the relevant value
266 selected. Analyses were performed using the R wrapper package brms [31] interfaced with Stan to
267 perform sampling.

268

269 2.7.1. *Estimations of typical variation*

270 With the control data, hourly typical variation of P1NP and β -CTX-1 markers was assessed by
271 estimating the mean difference and SD of difference of blood samples taken at rest before a running
272 bout [23, 32] or in a control group [15] compared to baseline. The typical daily variation of P1NP and
273 β -CTX-1 markers was assessed by estimating the mean difference and SD of difference of blood
274 samples taken 24-96 h post-baseline in control (non-exercise) groups [15, 16] compared to the baseline
275 collected on day 1.

276

277 3. Results

278 3.1. Data collection

279 3.1.1. *Running data*

280 From the selected studies by Dolan *et al.* [28], five studies were subsequently selected for inclusion in
281 the analysis of the current study [23, 24, 25, 32, 33]. One study from a PhD thesis of the university's
282 group was also included [29]. In total, six studies, with a total of 87 individuals, were included in the
283 analysis for the running data (**Table 1**). Individual participant data were collected from blood samples
284 measuring P1NP and β -CTX-1 markers at baseline and at all available time-points on each study during
285 and after the running bout (*i.e.*, 20 min during running, 30-40 min during running, 30 min post-running,

286 immediately after, 1 h post-running, 2 h post-running, 3 h post-running, 4 h post-running, 24 h post-
 287 running, 48 h post-running, 72 h post-running, and 96 h post-running). For time-points 30 min and 4h
 288 post-running, data were only available from one study and, therefore, were not included in the analyses.
 289

290 **Table 1.** List of studies included in the analysis.

Study	Running/control data	Bone (re)modelling markers	Assay used	Exercise duration/intensity
Evans <i>et al.</i> , 2020 [15]	Control	β -CTX-1 PINP	CLIA (IDS) CLIA (IDS)	-
Lehrskov <i>et al.</i> , 2020 [32]	Running and control	β -CTX-1 PINP	CLIA (IDS) CLIA (IDS)	60 min at 75% VO _{2max}
Sale <i>et al.</i> , 2015 [24]	Running	β -CTX-1 PINP	ECLIA (Roche) ECLIA (Roche)	120 min at 70% VO _{2max}
Scott <i>et al.</i> , 2010 [16]	Control	β -CTX-1 PINP	ECLIA (Roche) RIA (Orion)	-
Scott <i>et al.</i> , 2011 [33]	Running	β -CTX-1 PINP	ECLIA (Roche) RIA (Orion)	60 min at 65% or 75% VO _{2max}
Scott <i>et al.</i> , 2012 [23]	Running and control	β -CTX-1 PINP	ECLIA (Roche) RIA (Orion)	60 min at 65% VO _{2max}
Townsend <i>et al.</i> , 2017 [25]	Running	β -CTX-1 PINP	ECLIA (Roche) ECLIA (Roche)	~75 min at 75% VO _{2max}
Varley, 2014 [29]	Running	β -CTX-1	ELISA (IDS)	120 min at 70% VO _{2max}

291 *CLIA*, chemiluminescence immunoassay; *ECLIA*, electro-chemiluminescence assay; *ELISA*, Enzyme-linked
 292 immunosorbent assay; *PINP*, amino-terminal propeptide of type 1 procollagen; *RIA*, radioimmunoassay; β -CTX-
 293 1, carboxy-terminal telopeptide of type 1 collagen.
 294

295 3.1.2. Control data

296 From the six studies included for the running data, two [23, 32] collected blood samples (*i.e.*, 1-3
 297 samples) in resting (control) conditions before the running bout. Three additional studies [15, 16, 17],
 298 which fulfilled all inclusion criteria except the intervention characteristics, but included a non-exercise
 299 control group were also identified. However, individual participant data were only obtained, and thereby
 300 included, from two of these studies [15, 16] for the control data (**Table 1**). For these four studies [15,
 301 16, 23, 32], individual participant data were obtained from blood samples collected at baseline and
 302 during a 1-2.5 h period (hourly) and 24-96 h (daily) after the baseline sample in the control
 303 conditions/group. These data were used to estimate the hourly and daily PINP and β -CTX-1 mean
 304 difference and SD of the difference in control (resting) conditions.
 305

306 3.2. Typical hourly and daily variation of P1NP and β -CTX-1

307 The typical hourly and daily variation in P1NP and β -CTX-1 was determined by the mean difference
 308 and SD of the difference in control conditions (Table 2). There was limited evidence of a mean
 309 difference for hourly (0.06 [95% CrI -7.5 to 5.5] ng·mL⁻¹) and daily (-0.39 [95% CrI -4.3 to 2.9] ng·mL⁻¹)
 310 ¹) P1NP changes based on median estimates being close to zero and wide CrIs. Slightly higher variation
 311 in the hourly changes (\pm 7.6 [95% CrI 6.8 to 8.5] ng·mL⁻¹) were estimated compared with the daily
 312 changes (\pm 5.7 [95% CrI 5.1 to 6.5] ng·mL⁻¹). Stronger evidence was obtained for a mean difference for
 313 hourly β -CTX-1 changes, with the median and majority of the CrI indicating a decrease (-0.13 [95%
 314 CrI -0.34 to 0.06] ng·mL⁻¹). A wide CrI with median close to zero provided limited evidence of a mean
 315 difference for daily β -CTX-1 changes (-0.03 [95% CrI -0.54 to 0.30] ng·mL⁻¹). The SD of the difference
 316 was consistent between hourly (\pm 0.11 [95% CrI 0.11 to 0.12] ng·mL⁻¹) and daily (\pm 0.10 [95% CrI 0.09
 317 to 0.11] ng·mL⁻¹) changes of β -CTX-1. There was consistent evidence of heteroscedasticity with greater
 318 change score magnitudes for those with higher baselines.

319

320

321 **Table 2.** Hourly and daily typical variation of P1NP and β -CTX-1 in control conditions.

Marker	Studies	Number of participants and observations	Mean difference [95% CrI]	SD of difference [95% CrI]
Hourly				
P1NP (ng·mL ⁻¹)	Lehrskov <i>et al.</i> , 2020 [32]; Scott <i>et al.</i> , 2012 [23]; Evans <i>et al.</i> , 2020 [15]	Participants <i>n</i> = 27 Observations <i>n</i> = 58	0.06 [-7.5 to 5.5]	7.6 [6.8 to 8.5] ^a
β -CTX-1 (ng·mL ⁻¹)	Lehrskov <i>et al.</i> , 2020 [32]; Scott <i>et al.</i> , 2012 [23]; Evans <i>et al.</i> , 2020 [15]	Participants <i>n</i> = 27 Observations <i>n</i> = 58	-0.13 [-0.34 to 0.06]	0.11 [0.11 to 0.12] ^a
Daily				
P1NP (ng·mL ⁻¹)	Evans <i>et al.</i> , 2020 [15]; Scott <i>et al.</i> , 2010 [16]	Participants <i>n</i> = 22 Observations <i>n</i> = 52	-0.39 [-4.3 to 2.9]	5.7 [5.1 to 6.5] ^a
β -CTX-1 (ng·mL ⁻¹)	Evans <i>et al.</i> , 2020 [15]; Scott <i>et al.</i> , 2010 [16]	Participants <i>n</i> = 22 Observations <i>n</i> = 52	-0.03 [-0.54 to 0.30]	0.10 [0.09 to 0.11] ^a

322 ^a Evidence of heteroscedasticity

323

324 3.3. P1NP and β -CTX-1 responses to a prolonged, continuous running bout

325 3.3.1. Bone formation

326 In contrast to the control condition (0.06 [95% CrI -7.5 to 5.5] ng·mL⁻¹), there was clear evidence that
327 the levels of circulating P1NP increased during and immediately after the running bout with mean
328 differences of 4.2 [95% CrI 0.2 to 8.8] ng·mL⁻¹ at 20 min during the running bout, 9.2 [95% CrI 5.3 to
329 14.3] ng·mL⁻¹ at 30-40 min during the running bout, and 12.0 [95% CrI 8.4 to 16.0] ng·mL⁻¹
330 immediately after the running bout (**Table 3**). Greater SD of the difference was identified only at 30-
331 40 min during (± 8.1 [95% CrI 7.1 to 9.4] ng·mL⁻¹) and immediately (± 10.2 [95% CrI 9.3 to 11.3] ng·mL⁻¹)
332 after the running bout (**Table 3**) compared to the typical hourly variation (± 7.6 [95% CrI 6.8 to 8.5]
333 ng·mL⁻¹ (**Table 2**). For these three time-points (20 min during, 30-40 min during and immediately after)
334 the proportion of response was estimated as close to 100% (**Table 3**), indicating that close to all
335 participants would be expected to demonstrate an increase in P1NP levels. From one hour after finishing
336 the running bout and for the next three hours, P1NP returned to “normal” levels, with comparable mean
337 differences and SD of difference (**Table 3**) than the typical hourly variation (**Table 2**). Likewise, for
338 the four days (24-96 h) after the baseline in the running conditions, P1NP mean differences and SD of
339 the difference (**Table 3**) were comparable with the typical daily variation (**Table 2**). The proportion of
340 response was not estimated for these time-points due to these similarities and, therefore, there was a
341 lack of evidence of inter-individual response. There was evidence of heteroscedasticity across all time-
342 points except at 2 h and 72 h post-running.

343

344

345

346

347

348

349

350 **Table 3.** Responses of P1NP bone formation marker to a prolonged, continuous running bout.

P1NP (ng·mL ⁻¹)	Mean difference [95% CrI]	SD of difference [95% CrI]	P of increased variation	Proportion of response
Hourly				
20 min during running (25 observations / 2 studies)	4.2 [0.2 to 8.8]	6.1 [5.2 to 7.3] ^a	0.088	1.0 75% CrI [0.99 to 1.0]
30-40 during running (35 observations / 3 studies)	9.2 [5.3 to 14.3]	8.1 [7.1 to 9.4] ^a	0.700	1.0 75% CrI [0.99 to 1.0]
Immediately after (75 observations / 5 studies)	12.0 [8.4 to 16.0]	10.2 [9.3 to 11.3] ^a	>0.999	1.0 75% CrI [0.90 to 1.0]
1 hour post-running (75 observations / 5 studies)	1.1 [-3.1 to 5.2]	5.0 [4.5 to 5.6] ^a	< 0.001	-
2 hours post-running (60 observations / 4 studies)	0.6 [-3.1 to 4.3]	6.1 [5.5 to 6.8]	0.016	-
3 hours post-running (40 observations / 3 studies)	0.6 [-4.6 to 5.7]	4.6 [3.8 to 5.1] ^a	<0.001	-
Daily				
24 hours post-running (70 observations / 4 studies)	1.4 [-0.5 to 3.5]	5.2 [4.8 to 5.8] ^a	0.172	-
48 hours post-running (40 observations / 3 studies)	0.6 [-2.3 to 3.7]	5.9 [5.2 to 7.1] ^a	0.612	-
72 hours post-running (40 observations / 3 studies)	0.5 [-2.8 to 3.9]	7.8 [6.9 to 9.0]	0.999	-
96 hours post-running (30 observations / 2 studies)	-0.4 [-3.9 to 3.0]	5.4 [4.7 to 6.4] ^a	0.349	-

351 ^a Evidence of heteroscedasticity. Proportion of response was only calculated where there was strong evidence of
352 a mean difference.
353

354

355 3.3.2. Bone resorption

356 Although β -CTX-1 blood levels showed a small decrease in mean differences during the running bout
357 and for the four hours after finishing the running bout, the mean and SD of the differences (**Table 4**)
358 were similar to the β -CTX-1 typical hourly variation (-0.13 ± 0.11 ng·ml⁻¹) (**Table 2**). For the four days
359 (24-96 h) after the baseline in the running conditions, the distribution of the β -CTX-1 differences (**Table**
360 **4**) were similar to the β -CTX-1 typical daily variation (-0.03 ± 0.10 ng·ml⁻¹) (**Table 2**). The proportion
361 of response was not estimated for any time-points due to the small mean differences in the running
362 conditions and the similarities in the SD of the difference between running and control conditions. There

363 was evidence of heteroscedasticity across all time-points except for 72 h and 96 h post-running time-
 364 points.

365

366 **Table 4.** Responses of β -CTX-1 bone resorption marker to a prolonged, continuous running bout.

β -CTX-1 (ng·mL ⁻¹)	Mean difference [95% CrI]	SD of difference [95% CrI]	P of increased variation	Proportion of response
Hourly				
20 min during running (25 observations / 2 studies)	-0.09 [-0.55 to 0.37]	0.04 [0.03 to 0.05] ^a	< 0.001	-
30-40 during running (35 observations / 3 studies)	-0.06 [-0.29 to 0.14]	0.10 [0.08 to 0.11] ^a	0.563	-
Immediately after (116 observations / 6 studies)	-0.01 [-0.09 to 0.06]	0.13 [0.12 to 0.14] ^a	0.996	-
1 hour post-running (60 observations / 4 studies)	-0.02 [-0.13 to 0.08]	0.10 [0.09 to 0.12] ^a	0.244	-
2 hours post-running (60 observations / 4 studies)	-0.08 [-0.18 to 0.01]	0.10 [0.09 to 0.11] ^a	0.109	-
3 hours post-running (40 observations / 3 studies)	-0.13 [-0.36 to 0.03]	0.11 [0.10 to 0.13] ^a	0.576	-
Daily				
24 hours post-running (111 observations / 5 studies)	0.01 [-0.02 to 0.04]	0.12 [0.11 to 0.13] ^a	> 0.999	-
48 hours post-running (81 observations / 4 studies)	0.01 [-0.06 to 0.07]	0.15 [0.14 to 0.16] ^a	> 0.999	-
72 hours post-running (81 observations / 4 studies)	0.06 [-0.09 to 0.19]	0.32 [0.29 to 0.35]	> 0.999	-
96 hours post-running (30 observations / 2 studies)	-0.03 [-0.27 to 0.24]	0.09 [0.08 to 0.11]	0.311	-

380

^a Evidence of heteroscedasticity. Proportion of response was only calculated where there was strong evidence of a mean difference.

3.4. Risk of bias assessment

The application of the modified Downs and Black [30] checklist (**Supplementary file 2**) resulted in the classification of seven studies as high quality and two studies as moderate quality (**Table 5**). The most common reasons why studies were downgraded were because of lack of details provided regarding the storage and handling of the blood samples [15, 16], the lack of specification of the standardisation of the exact time of the day when the fasted morning baseline was collected [15, 32], and the inadequate

381 or absent standardisation/monitoring of important nutrition and diet variables [15, 29, 32]. All running
382 studies [23, 24, 25, 29, 32, 33] were downgraded because the during and post running data were not
383 corrected for shifts in plasma volume.

384

385 **Table 5.** Risk of bias in individual studies.

Study	Score	Quality
Evans <i>et al.</i> , 2020 [15]	17/20	!
Lehrskov <i>et al.</i> , 2020 [32]	16/20	!
Sale <i>et al.</i> , 2015 [24]	19/20	+
Scott <i>et al.</i> , 2010 [16]	19/20	+
Scott <i>et al.</i> , 2011 [33]	18/20	+
Scott <i>et al.</i> , 2012 [23]	19/20	+
Townsend <i>et al.</i> , 2017 [25]	19/20	+
Varley, 2014 [29]	18/20	+

386

387 Green circle, high quality; yellow circle, moderate quality

388

389

390

391

392

393

394

395

396

397

398

399

400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441




Figure 2. P1NP differences (y axis) from baseline (x axis) during 20 min, 30-40 min, immediately post, 1 h post, 2 h post, and 3 h post a continuous, prolonged running bout. Orange: Scott *et al.*, 2011 [33]; blue: Lehrskov *et al.*, 2020 [32]; green: Scott *et al.*, 2012 [23]; red: Sale *et al.*, 2015 [24]; yellow: Townsend *et al.*, 2017 [25]. The grey shaded area represents 95% CrI of the mean difference in control conditions (typical hourly variation).

442
443

444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473




Figure 3. P1NP differences (y axis) from baseline (x axis) 24 h post, 48 h post, 72 h post, and 96 h post a continuous, prolonged running bout. Orange: Scott *et al.*, 2011 [33]; green: Scott *et al.*, 2012 [23]; red: Sale *et al.*, 2015 [24]; yellow: Townsend *et al.*, 2017 [25]. The grey shaded area represents 95% CrI of the mean difference in control conditions (typical daily variation).

474
475
476
477
478
479
480
481
482
483
484
485
486
487
488

489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532




Figure 4. β -CTX-1 differences (y axis) from baseline (x axis) during 20 min, 30-40 min, immediately post, 1 h post, 2 h post, and 3 h post a continuous, prolonged running bout. Orange: Scott *et al.*, 2011 [33]; blue: Lehrskov *et al.*, 2020 [32]; green: Scott *et al.*, 2012 [23]; red: Sale *et al.*, 2015 [24]; yellow: Townsend *et al.*, 2017 [25] pink: Varley, 2014 [29]. The grey shaded area represents 95% CrI of mean difference in control

533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563




Figure 5. β -CTX-1 differences (y axis) from baseline (x axis) 24 h post, 48 h post, 72 h post, and 96 h post a continuous, prolonged running bout. Orange: Scott *et al.*, 2011 [33]; green: Scott *et al.*, 2012 [23]; red: Sale *et al.*, 2015 [24]; yellow: Townsend *et al.*, 2017 [25]; pink: Varley, 2014 [29]. The grey shaded area represents 95% CrI of mean difference in control conditions (typical daily variation).

564
565
566
567
568
569

568 4. Discussion

569 The key findings of the study were that: (i) P1NP increased exclusively during and immediately after
570 running, and there was a lack of evidence of changes in β -CTX-1 linked to running, (ii) the inter-
571 individual variability of P1NP and β -CTX-1 change scores were similar between resting (control)
572 conditions and during and after running, except for P1NP levels during and immediately after the
573 running bout, and, therefore, (iii) there was an overall lack of inter-individual response in P1NP and β -
574 CTX-1 linked to running, with reported decreases in β -CTX during the hours after running not being
575 attributable to the running intervention.

576

577 Increases in P1NP levels were limited to during and immediately after exercise, and this consistently
578 occurred within all participants (estimated proportion of response \sim 100%). Because these changes were
579 sudden and transient, however, it seems unlikely that they reflect any meaningful increase in bone
580 formation. Similar results were reported in the recent meta-analysis by Dolan *et al.*, [28], where they
581 pooled the acute responses of bone (re)modelling markers after different exercise interventions,
582 showing increases in P1NP within 15 minutes of the cessation of exercise. It is possible that this
583 transient increase in circulating P1NP could be due to leakage of P1NP from the connective tissue into
584 the circulation or due to haemodynamic shifts. P1NP is not a bone-specific marker and can be affected
585 by the metabolism of collagen from other tissues [26]. Although fluids were provided during the running
586 bout in two studies [24, 33]; shifts in plasma volume were not accounted for in any of the running
587 studies included in this review, which could contribute toward explaining the transiently higher
588 concentrations. Brahm *et al.* [34] reported similar, sudden and transient, increases in C-terminal
589 propeptide of type 1 procollagen (P1CP) in young individuals after a running to exhaustion intervention
590 with a total duration of \sim 35 minutes, which mirrored changes in plasma volume (showing decreases
591 following the same pattern) and corresponded to increases in haematocrit. They reported no significant
592 changes in P1CP when correcting for plasma volume shifts [34]. As such, it seems plausible that the
593 increases observed herein are due to biological artefact, rather than as representing an actual increase
594 in bone formative processes.

595 The stimulation of bone formation in response to exercise may require a longer period, although how
596 long exactly may be required is currently unknown. Our statistical model based on available data led to
597 the conclusion of no change in P1NP levels in the 1-3 hours and 1-4 days post-running, which indicates
598 that a single prolonged, continuous running bout did not stimulate bone formation, at least up until the
600 fourth day after the running bout. Most studies that have measured bone (re)modelling markers after an
601 acute exercise intervention have only done so for a few days (1-3 days) after the intervention [35, 36,
602 37, 38, 39, 40] and, therefore, there is no data available on longer-term changes of bone formation
603 markers in response to a single exercise session. In contrast, longitudinal studies in healthy adult
604 populations looking at the chronic responses of bone (re)modelling markers to repeated exercise
605 training of various types have consistently shown increased resting levels of bone formation markers,
606 including P1NP [41, 42, 43, 44, 45, 46, 47, 48, 49, 50]. Therefore, bone formation responses measured
607 by changes in P1NP levels might take longer than the 4 days used in studies thus far.

608

609 For circulating levels of β -CTX-1, despite showing small decreases during and in the hours after
610 running, there is no evidence that these changes were caused by the running intervention, given that
611 they were similar in magnitude to the reductions shown in the non-exercise control data. Together, these
612 results suggest that the small decreases in circulating β -CTX-1 shown during and in the hours after
613 running were caused by measurement error rather than as a result of the running intervention. These
614 reductions in β -CTX-1 coincide with the circadian rhythm of this biomarker under fasting conditions
615 [14], peaking in the early morning and declining in the later morning hours [51, 52].

616

617 Furthermore, aggregate meta-analytic evidence [28] suggests that β -CTX-1 responses to exercise are
618 influenced by the type of exercise, with moderate to large increases shown from 15 minutes to 2 hours
619 after long-duration cycling. Increases in β -CTX-1 could be explained by increases in parathyroid
620 hormone (PTH), triggered by reductions in serum calcium, that subsequently stimulates osteoclastic
621 bone resorption [53]. Although this mechanism seems to agree with the β -CTX-1 increases to cycling

622 interventions [54], it does not explain the lack of a response reported herein, given that increased
623 PTH has also been observed in response to similar running bouts as were investigated herein [23, 24, 25,
624 33].

625 For the 1-4 days after the running bout, β -CTX-1 blood levels were also similar to the daily typical
626 variation determined by the control data, indicating that the running intervention did not yield
627 significant responses to β -CTX-1 circulating levels. Similar results were reported by the Dolan *et al.*
628 [28] meta-analysis, which included studies with different designs and exercise interventions, although
629 they showed some evidence of increases in β -CTX-1 at 72 hours post-exercise. The lack of a response
630 (*i.e.*, increase) in β -CTX-1 shown herein, could be considered as a beneficial outcome for bone
631 adaptations if it is interpreted as the lack of resorption activity that can lead to bone loss. In contrast,
632 the initial increase in bone resorption markers could be indicative of the activation of the bone
633 (re)modelling cycle [55]. In this case, it could be concluded that a single running bout does not stimulate
634 bone remodelling, at least within the next four days. Bone (re)modelling is, however, a nuanced process
635 that is continuously ongoing at different stages across different skeletal sites and site-specific bone
636 adaptations to exercise interventions might not be reflected by systemic bone (re)modelling markers.

637

638 **4.1. Strengths and limitations**

639 Studies included in this meta-analysis were classified as high quality ($n = 8$) overall. It should be noted,
640 however, that the inclusion criteria applied herein was thorough and delimited; and, therefore, low
641 quality studies would likely not have met this criterion. In the Dolan *et al.* [28] meta-analysis, which
642 had a less restricted inclusion criteria and included a larger number of studies ($n = 99$), the general
643 quality of the studies was reported as moderate. While a more inclusive criteria would have allowed the
644 inclusion of a greater number of studies and, thereby, more data points; it would have also added more
645 variability. The aim of this meta-analysis was to investigate the responses of P1NP and β -CTX-1 in
646 very specific conditions by reducing potential sources of variability, such as the type of exercise
647 intervention (*i.e.*, impact level, duration, and intensity, intermittent/continuous), participant
648 characteristics (*i.e.*, age, sex, and health status) and study design (*i.e.*, feeding/fasting conditions, time

649 of the day). Removing these sources of variability allowed for a better understanding of the inter-
650 individual variability caused by factors external to the intervention itself, such as circadian variation.

651

652 This systematic review with individual participant data meta-analysis was not without limitations,
653 including those inherited from the included studies. Although all included studies collected a baseline
654 sample in the morning, the exact time of the day when the fasted baseline sample was taken only varied
655 from 0800-0840 but was not specified in two studies [15, 32]. Similarly, the exact time of the day when
656 the running bout began was different across studies. These factors could have impacted the changes in
657 bone (re)modelling markers; particularly β -CTX-1, which has a more pronounced variation due to its
658 circadian rhythm [14]. Additionally, habitual dietary and nutritional factors, such as energy availability,
659 macronutrient composition of the diet and vitamin D and calcium intakes were not controlled in the
660 included studies, and could have affected P1NP and β -CTX-1 baseline levels (for a review please see
661 [56]). The baseline level of a marker might be an important variable determining the subsequent
662 response to exercise, and potentially to other interventions as well, as the heteroscedasticity shown in
663 the participant data of this meta-analysis suggested that those participants with higher baselines had
664 greater changes for both markers and across time-points and requires further investigation.

665

666 Only two studies included a non-exercise control group, which means that the control data used to
667 estimate the typical variation of P1NP and β -CTX-1 in resting conditions was predominantly from
668 different participants (although with similar characteristics). It is possible that the inter-individual
669 variability was greater than if all participant control data had been obtained from the same running
670 participants. Nonetheless, the mean differences and variability (*i.e.*, SD of the difference) in P1NP and
671 β -CTX-1 were similar between the control and running data. For the running data, the running
672 interventions of the included studies had a relatively limited range of durations and intensities, which
673 could have added variability in our results. While exercise duration, intensity, and total work done might
674 modulate bone (re)modelling markers responses [28, 33], the consistency and relevance of these effects
675 is unclear with the current evidence. Nonetheless, the mean differences and variability (*i.e.*, SD of the
676 difference) in P1NP and β -CTX-1 were similar between the control and running data. Another factor

677 that could have increased variability in all data is the measurement error from the instrumentation (*e.g.*,
678 variation of analytical assays used to measure bone biomarkers in the included studies). Various types
679 of assays were used across studies, which have different intra- and inter-assay coefficients of variation,
680 generally ranging from 1.4-4.9% (P1NP) and 2.1-5.3% (β -CTX-1) [57]. This variation can be critical
681 for exercise research given the overall small responses that bone (re)modelling markers exhibit after
682 acute exercise interventions [28]. For example, β -CTX-1 samples analysed using ELISA methods, as
683 in the Varley [29] study, seem to yield higher variability in the data (**Figures 4 and 5**, pink dots)
684 compared to others.

685

686 The current meta-analysis only included studies with a running intervention in young healthy adult
687 males because similar studies in female populations are lacking. Available literature on P1NP and/or β -
688 CTX-1 responses to exercise in females usually involves post-menopausal populations [40, 58, 59].
689 Only a limited number of studies have investigated the acute responses of reference markers P1NP
690 and/or β -CTX-1 to exercise (*e.g.*, jogging, brisk walking with resistance training, football) in young
691 females [40, 60, 61]. No studies have directly compared these responses between males and females;
692 however, in their meta-analysis, Dolan and colleagues [28] showed that sex did not influence exercise-
693 associated changes of markers P1NP and β -CTX-1. In addition, studies in older male populations in
694 this area are also lacking, and older-adults might have different β -CTX-1 responses to aerobic exercise
695 as highlighted in a recent systematic review [62], hence, results from the current study might not
696 translate to older populations.

697

698 **4.2. Implications for future research**

699 The majority of studies included in this meta-analysis did not include a control (non-exercise) group
700 because they were designed to investigate how various factors (*e.g.*, nutrition, exercise intensity) may
701 moderate the bone (re)modelling marker responses to a running bout. Indeed, this study design is
702 commonly used within exercise research and only about a quarter of studies looking at acute exercise
703 responses of bone (re)modelling markers included a control group [28]. It is recommended that non-
704 exercise control groups are included in future studies to quantify the variability of the instrumentation

705 noise (*i.e.*, from assays) and biological noise (*e.g.*, from circadian rhythms) [18], and to establish if
706 exercise interventions of different kinds produce an effect on bone (re)modelling markers.

707
708 Bone (re)modelling markers have not yet been validated or linked to a primary reference measurement
709 because there is no alternative reference measurement system available that can act as a higher order
710 standard or gold standard [57]; and it is not clear whether they can predict changes detected by imaging
711 techniques, such as dual-energy X-ray absorptiometry (DXA) or peripheral quantitative computed
712 tomography (pQCT) [26]. Bone (re)modelling markers are systemic and do not necessarily represent
713 local bone adaptations/changes. Therefore, studies utilising bone (re)modelling markers to investigate
714 the bone responses to acute or short-term exercise interventions will likely be missing key information
715 about the local effects that loading has on the skeleton and they need to be interpreted with
716 understanding of this limitation.

717
718 It is important that studies including bone (re)modelling markers adhere to the recommended
719 standardisation guidelines [26, 57, 63], control important factors before the intervention (*e.g.*, nutrition,
720 sleep, physical activity), clearly report the time of the day of all measures, sampling timing, storage,
721 and handling of the samples, and report assay quality control information, which would reduce inter-
722 individual variability and help when making comparisons with other studies. Given the potentially
723 misleading increases in P1NP during and immediately post-running reported herein, studies should also
724 consider shifts in plasma volume and fluid lost or report both adjusted and unadjusted data for changes
725 in plasma volume.

726

727 **4.3. Summary and conclusions**

728 This individual participant data meta-analysis determined that a prolonged, continuous bout of treadmill
729 running (60-120 min at 65-75% $\text{VO}_{2\text{max}}$) does not result in changes in bone (re)modelling, as determined
730 by P1NP and β -CTX-1, in young healthy adult males. Whilst there was evidence of a transient increase
731 of P1NP during and immediately after running, this response was likely caused by biological aspects
732 (*e.g.*, shifts in plasma volume, leakage from other connective tissues) rather than being reflective of

733 bone formation. Similar small decreases in β -CTX-1 were shown in control and running data,
734 suggesting that these changes were due to the marker's circadian rhythm and not the running
735 intervention. Hence, it remains unclear whether a single running bout produces bone adaptations, but
736 indirect bone (re)modelling markers P1NP and β -CTX-1 markers failed to capture any potential
737 responses. There is a need for individual studies that investigate the acute responses of bone
738 (re)modelling markers to different types of exercise and across different populations, which include a
739 control (non-exercise) group.

740

741

742 **Declarations**

743 **Availability of data**

744 Data are available on request from the authors.

745

746 **Competing interests**

747 All authors declare no competing interests relevant to the content of this review.

748

749 **Funding**

750 This work was completed as part of the PhD programme of work for RC, for which she received funding
751 from the Nottingham Trent University Vice Chancellors Studentship Scheme. ED is financially
752 supported by the *Fundação de Amparo à Pesquisa do Estado do São Paulo* (FAPESP: 2019/05616-6
753 and 2019/26899-6), which allowed her the time to contribute to this work.

754

755 **Authors' contributions**

756 RC, ED, and CS conceived the original idea for this article and the protocol was developed by RC, ED,
757 PAS, and CS, with critical input from LS, IV, PJA, and KJES. RC conducted the selection of studies
758 and data extraction. RC and CS evaluated the risk of bias, and PAS conducted all statistical analyses.

759 RC wrote the initial manuscript draft, which was then revised according to critical input from all
760 authors. All authors read and approved the final manuscript.

761

762 **Acknowledgements**

763 This study was presented as an oral presentation at the 27th Annual Congress of the European College
764 of Sport Science (30 August -02 September 2022) with the abstract title *PINP and β -CTX-I responses*
765 *to a prolonged, continuous running bout in healthy adult males: a systematic review and individual*
766 *participant data meta-analysis*. We would like to thank the authors of the selected studies that provided
767 the individual participant data upon request for their collaboration and support.

768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794

References

1. Kelley GA, Kelley KS, Tran ZV. Exercise and bone mineral density in men: a meta-analysis. *J Appl Physiol.* 2000;88(5):1730–6. <https://doi.org/10.1152/jappl.2000.88.5.1730>
2. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and adolescents: A review of controlled trials. *Bone.* 2007;40(1):14–27. <https://doi.org/10.1016/j.bone.2006.07.006>
3. Marques EA, Mota J, Carvalho J. Exercise effects on bone mineral density in older adults: A meta-analysis of randomized controlled trials. *Age.* 2012;34(6):1493–515. <https://doi.org/10.1007/s11357-011-9311-8>
4. Kelley GA, Kelley KS, Kohrt WM. Exercise and bone mineral density in men: A meta-analysis of randomized controlled trials. *Bone.* 2013;53(1):103–11. <https://doi.org/10.1016/j.bone.2012.11.031>
5. O'Connor JA, Lanyon LE, MacFie H. The influence of strain rate on adaptive bone remodelling. *J Biomech.* 1982;15(10):767-81. [https://doi.org/10.1016/0021-9290\(82\)90092-6](https://doi.org/10.1016/0021-9290(82)90092-6)
6. Lanyon LE, Rubin CT. Static vs dynamic loads as an influence on bone remodelling. *J Biomech.* 1984;17(12):897-905. [https://doi.org/10.1016/0021-9290\(84\)90003-4](https://doi.org/10.1016/0021-9290(84)90003-4)
7. Rubin CT, Lanyon LE. Regulation of bone mass by mechanical strain magnitude. *Calcif Tissue Int.* 1985 Jul;37(4):411-7. <https://doi.org/10.1007/BF02553711>
8. Turner CH, Robling AG. Designing exercise regimens to increase bone strength. *Exerc Sport Sci Rev.* 2003 Jan;31(1):45-50. <https://doi.org/10.1097/00003677-200301000-00009>
9. Rector RS, Rogers R, Ruebel M, Hinton PS. Participation in road cycling vs running is associated with lower bone mineral density in men. *Metabolism.* 2008;57(2):226–32. <https://doi.org/10.1016/j.metabol.2007.09.0055>
10. Arendt E, Agel J, Heikes C, Griffiths H. Stress Injuries to Bone in College Athletes. A Retrospective Review of Experience at a Single Institution. *Am J Sports Med.* 2003;31(6):959–68. <https://doi.org/10.1177/0363546503031006360>

- 795 11. Scofield KL, Hecht S. Bone health in endurance athletes: Runners, cyclists, and swimmers.
796 Curr Sports Med Rep. 2012;11(6):328–34. <https://doi.org/10.1249/JSR.0b013e3182779193>
- 797 12. Hind K, Truscott JG, Evans JA. Low lumbar spine bone mineral density in both male and
798 female endurance runners. Bone. 2006;39(4):880–5.
799 <https://doi.org/10.1016/j.bone.2006.03.012>
- 800 13. Hoenig T, Ackerman KE, Beck BR, Bouxsein ML, Burr DB, Hollander K, Popp KL, Rolvien
801 T, Tenforde AS, Warden SJ. Bone stress injuries. Nat Rev Dis Primers. 2022 Apr 28;8(1):26.
802 <https://doi.org/10.1038/s41572-022-00352-y>
- 803 14. Diemar SS, Dahl SS, West AS, Simonsen SA, Iversen HK, Jørgensen NR. A Systematic
804 Review of the Circadian Rhythm of Bone Markers in Blood. Calcif Tissue Int. 2022 Mar 19.
805 <https://doi.org/10.1007/s00223-022-00965-1>
- 806 15. Evans W, Nevill A, McLaren SJ, Ditroilo M. The effect of intermittent running on biomarkers
807 of bone turnover. Eur J Sport Sci. 2020;20(4):505–15.
808 <https://doi.org/10.1080/17461391.2019.1646811>
- 809 16. Scott JPR, Sale C, Greeves JP, Casey A, Dutton J, Fraser WD. The effect of training status on
810 the metabolic response of bone to an acute bout of exhaustive treadmill running. J Clin
811 Endocrinol Metab. 2010;95(8):3918–25. <https://doi.org/10.1210/jc.2009-2516>
- 812 17. Alkahtani SA, Yakout SM, Reginster JY, Al-Daghri NM. Effect of acute downhill running on
813 bone markers in responders and non-responders. Osteoporos Int. 2019;30(2):375–81.
814 <https://doi.org/10.1007/s00198-018-4673-8>
- 815 18. Swinton PA, Hemingway BS, Saunders B, Gualano B, Dolan E. A Statistical Framework to
816 Interpret Individual Response to Intervention: Paving the Way for Personalized Nutrition and
817 Exercise Prescription. Front Nutr. 2018;5(May). <https://doi.org/10.3389/fnut.2018.00041>
- 818 19. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: Rationale,
819 conduct, and reporting. BMJ. 2010;340(7745):521–5. <https://doi.org/10.1136/bmj.c221>
- 820 20. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting
821 items for a systematic review and meta-analysis of individual participant data: The PRISMA-
822 IPD statement. JAMA - J Am Med Assoc. 2015;313(16):1657–65.

- 823 <https://doi.org/10.1001/jama.2015.3656>
- 824 21. Page M, McKenzie J, Patrick B, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020
825 statement: an updated guideline for reporting systematic reviews. *Syst Rev.* 2021 Mar
826 29;10(1):89. <https://doi.org/10.1186/s13643-021-01626-4>
- 827 22. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the
828 serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of
829 gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. *Bone.*
830 2002;31(1):57–61. [https://doi.org/10.1016/S8756-3282\(02\)00791-3](https://doi.org/10.1016/S8756-3282(02)00791-3)
- 831 23. Scott JPR, Sale C, Greeves JP, Casey A, Dutton J, Fraser WD. Effect of fasting versus feeding
832 on the bone metabolic response to running. *Bone.* 2012;51(6):990–9. [http://doi.org/](http://doi.org/10.1016/j.bone.2012.08.128)
833 [10.1016/j.bone.2012.08.128](http://doi.org/10.1016/j.bone.2012.08.128)
- 834 24. Sale C, Varley I, Jones TW, James RM, Tang JCY, Fraser WD, et al. Effect of carbohydrate
835 feeding on the bone metabolic response to running. *J Appl Physiol.* 2015;119(7):824–30.
836 <https://doi.org/10.1152/jappphysiol.00241.2015>
- 837 25. Townsend R, Elliott-Sale KJ, Currell K, Tang J, Fraser WD, Sale C. The effect of postexercise
838 carbohydrate and protein ingestion on bone metabolism. *Med Sci Sports Exerc.*
839 2017;49(6):1209–18. <https://doi.org/10.1249/MSS.0000000000001211>
- 840 26. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garner P, Griesmacher A, et al. Markers of
841 bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A
842 need for international reference standards. *Osteoporos Int.* 2011;22(2):391–420.
843 <https://doi.org/10.1007/s00198-010-1501-1>
- 844 27. Dolan E, Dumas A, Keane KM, Bestetti G, Freitas LHM, Gualano B, et al. The influence of
845 acute exercise on bone biomarkers: protocol for a systematic review with meta-analysis. *Syst*
846 *Rev.* 2020;9(1):1–9. <https://doi.org/10.1186/s13643-020-01551-y>
- 847 28. Dolan E, Dumas A, Keane KM, Bestetti G, Freitas LHM, Gualano B, Kohrt WM, Kelley GA,
848 Pereira RMR, Sale C, Swinton PA. The Bone Biomarker Response to an Acute Bout of
849 Exercise: A Systematic Review with Meta-Analysis. *Sports Med.* 2022; Dec;52(12):2889-08.
850 <https://doi.org/10.1007/s40279-022-01718-8>

- 851 29. Varley, I. Association of genotype with bone metabolism, skeletal adaptation and stress fracture
852 injury occurrence. PhD, Nottingham Trent University. 2014. <https://llr.ntu.ac.uk>
- 853 30. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the
854 methodological quality both of randomised and non-randomised studies of health care
855 interventions. *J Epidemiol Community Health*. 1998;52(6):377–84.
856 <https://doi.org/10.1136/jech.52.6.377>
- 857 31. Bürkner PC. brms: An R package for Bayesian multilevel models using Stan. *Journal of*
858 *statistical software*. 2017; Aug 29;80:1-28. <https://doi.org/10.18637/jss.v080.i01>
- 859 32. Lehrskov LL, Kjeldsen S, Lyngbæk MP, Chirstensen RH, Wedell-Neergaard AS, Søderlund L,
860 et al. Interleukin-6 May not affect bone resorption marker CTX or bone formation marker PINP
861 in humans. *J Endocr Soc*. 2020;4(9):1–12. <https://doi.org/10.1210/jendso/bvaa093>
- 862 33. Scott JPR, Sale C, Greeves JP, Casey A, Dutton J, Fraser WD. The role of exercise intensity in
863 the bone metabolic response to an acute bout of weight-bearing exercise. *J Appl Physiol*.
864 2011;110(2):423–32. <https://doi.org/10.1152/jappphysiol.00764.2010>
- 865 34. Brahm H, Piehl-Aulin K, Ljunghall S. Bone metabolism during exercise and recovery: The
866 influence of plasma volume and physical fitness. *Calcif Tissue Int*. 1997;61(3):192–8.
867 <https://doi.org/10.1007/s002239900322>
- 868 35. Herrmann M, Müller M, Scharhag J, Sand-Hill M, Kindermann W, Herrmann W. The effect of
869 endurance exercise-induced lactacidosis on biochemical markers of bone turnover. *Clin Chem*
870 *Lab Med*. 2007;45(10):1381–9. <https://doi.org/10.1515/CCLM.2007.282>
- 871 36. Guerriere KI, Hughes JM, Gaffney-Stomberg E, Staab JS, Matheny RW. Circulating sclerostin
872 is not suppressed following a single bout of exercise in young men. *Physiol Rep*. 2018;6(10):1–
873 9. <https://doi.org/10.14814/phy2.13695>
- 874 37. Kouvelioti R, Kurgan N, Falk B, Ward WE, Josse AR, Klentrou P. Response of sclerostin and
875 bone turnover markers to high intensity interval exercise in young women: Does impact matter?
876 *Biomed Res Int*. 2018 Nov 1;2018:4864952. <https://doi.org/10.1155/2018/4864952>
- 877 38. Clifford T, Ventress M, Allerton DM, Stansfield S, Tang JCY, Fraser WD, et al. The effects of
878 collagen peptides on muscle damage, inflammation and bone turnover following exercise: a

- 879 randomized, controlled trial. *Amino Acids*. 2019;51(4):691–704.
880 <https://doi.org/10.1007/s00726-019-02706-5>
- 881 39. Kouvelioti R, LeBlanc P, Falk B, Ward WE, Josse AR, Klentrou P. Effects of High-Intensity
882 Interval Running Versus Cycling on Sclerostin, and Markers of Bone Turnover and Oxidative
883 Stress in Young Men. *Calcif Tissue Int*. 2019;104(6):582–90. Available from:
884 <https://doi.org/10.1007/s00223-019-00524-1>
- 885 40. Nelson K, Kouvelioti R, Theocharidis A, Falk B, Tiidus P, Klentrou P. Osteokines and bone
886 markers at rest and following plyometric exercise in pre-and postmenopausal women. *Biomed*
887 *Res Int*. 2020 Oct 21;2020:7917309. <https://doi.org/10.1155/2020/7917309>
- 888 41. Fujimura R, Ashizawa N, Watanabe M, Mukai N, Amagai H, Fukubayashi T, et al. Effect of
889 resistance exercise training on bone formation and resorption in young male subjects assessed
890 by biomarkers of bone metabolism. *J Bone Miner Res*. 1997;12(4):656–62.
891 <https://doi.org/10.1359/jbmr.1997.12.4.656>
- 892 42. Tajima O, Ashizawa N, Ishii T, Amagai H, Mashimo T, Liu LJ, et al. Interaction of the effects
893 between vitamin D receptor polymorphism and exercise training on bone metabolism. *J Appl*
894 *Physiol*. 2000;88(4):1271–6. <https://doi.org/10.1152/jappl.2000.88.4.1271>
- 895 43. Adami S, Gatti D, Viapiana O, Fiore CE, Nuti R, Luisetto G, et al. Physical activity and bone
896 turnover markers: A cross-sectional and a longitudinal study. *Calcif Tissue Int*.
897 2008;83(6):388–92. <https://doi.org/10.1007/s00223-008-9184-8>
- 898 44. Kim S, Sherk V, Bemben M, Bemben D. Effects Of Short Term Low Intensity Resistance
899 Training With Kaatsu On Bone Metabolic Markers In Untrained Young Men. *Med Sci Sport*
900 *Exerc*. 2009;41(5):76–7. <https://doi.org/10.1249/01.mss.0000353505.78729.ef>
- 901 45. Lester ME, Urso ML, Evans RK, Pierce JR, Spiering BA, Maresh CM, et al. Influence of
902 exercise mode and osteogenic index on bone biomarker responses during short-term physical
903 training. *Bone*. 2009;45(4):768–76. <https://doi.org/10.1016/j.bone.2009.06.001>
- 904 46. Erickson CR, Vukovich MD. Osteogenic index and changes in bone markers during a jump
905 training program: A pilot study. *Med Sci Sports Exerc*. 2010;42(8):1485–92.
906 <https://doi.org/10.1249/MSS.0b013e3181d0fa7a>

- 907 47. Hu M, Finni T, Xu L, Zou L, Cheng S. Effects of resistance training on biomarkers of bone
908 formation and association with red blood cell variables. *J Physiol Biochem.* 2011;67(3):351–8.
909 <https://doi.org/10.1007/s13105-011-0082-6>
- 910 48. Ardawi MSM, Rouzi AA, Qari MH. Physical activity in relation to serum sclerostin, insulin-
911 like growth factor-1, and bone turnover markers in healthy premenopausal women: A cross-
912 sectional and a longitudinal study. *J Clin Endocrinol Metab.* 2012;97(10):3691–9.
913 <https://doi.org/10.1210/jc.2011-3361>
- 914 49. Lutz LJ, Karl JP, Rood JC, Cable SJ, Williams KW, Young AJ, et al. Vitamin D status, dietary
915 intake, and bone turnover in female Soldiers during military training: A longitudinal study. *J*
916 *Int Soc Sports Nutr.* 2012;9(1):1. <https://doi.org/10.1186/1550-2783-9-38>
- 917 50. Kim SJ, Bemben MG, Knehans AW, Bemben DA. Effects of an 8-month ashtanga-based yoga
918 intervention on bone metabolism in middle-aged premenopausal women: A randomized
919 controlled study. *J Sport Sci Med.* 2015 Nov 24;14(4):756-68. PMID: 26664272
- 920 51. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P,
921 Alexandersen P, et al. Serum CrossLaps for monitoring the response in individuals undergoing
922 antiresorptive therapy. *Bone.* 2000;26(5):505–11.
923 [https://doi.org/10.1016/S8756-3282\(00\)00248-9](https://doi.org/10.1016/S8756-3282(00)00248-9)
- 924 52. Bjarnason NH, Henriksen EEG, Alexandersen P, Christgau S, Henriksen DB, Christiansen C.
925 Mechanism of circadian variation in bone resorption. *Bone.* 2002;30(1):307–13.
926 [https://doi.org/10.1016/S8756-3282\(01\)00662-7](https://doi.org/10.1016/S8756-3282(01)00662-7)
- 927 53. Wherry SJ, Swanson CM, Kohrt WM. Acute catabolic bone metabolism response to exercise
928 in young and older adults: A narrative review. *Exp Gerontol.* 2022;157(May 2021):111633.
929 <https://doi.org/10.1016/j.exger.2021.111633>
- 930 54. Kohrt WM, Wherry SJ, Wolfe P, Sherk VD, Wellington T, Swanson CM, et al. Maintenance
931 of Serum Ionized Calcium During Exercise Attenuates Parathyroid Hormone and Bone
932 Resorption Responses. *J Bone Miner Res.* 2018;33(7):1326–34.
933 <https://doi.org/10.1002/jbmr.3428>
- 934 55. Robling AG, Castillo AB, Turner CH. Biomechanical and molecular regulation of bone

- 935 remodeling. *Annu Rev Biomed Eng.* 2006;8:455–98.
936 <https://doi.org/10.1146/annurev.bioeng.8.061505.095721>
- 937 56. Dolan E, Varley I, Ackerman KE, Pereira RMR, Elliott-Sale KJ, Sale C. The Bone Metabolic
938 Response to Exercise and Nutrition. *Exerc Sport Sci Rev.* 2020 Apr;48(2):49-58.
939 <https://doi.org/10.1249/JES.0000000000000215>
- 940 57. Bhattoa HP, Cavalier E, Eastell R, Heijboer AC, Jørgensen NR, Makris K, et al. Analytical
941 considerations and plans to standardize or harmonize assays for the reference bone turnover
942 markers PINP and β -CTX in blood. *Clin Chim Acta.* 2021;515(September 2020):16–20.
943 <https://doi.org/10.1016/j.cca.2020.12.023>
- 944 58. Shea KL, Barry DW, Sherk VD, Hansen KC, Wolfe P, Kohrt WM. Calcium supplementation
945 and parathyroid hormone response to vigorous walking in postmenopausal women. *Med Sci*
946 *Sports Exerc.* 2014;46(10):2007–13. <https://doi.org/10.1249/MSS.0000000000000320>
- 947 59. Prawiradilaga RS, Madsen AO, Jørgensen NR, Helge EW. Acute response of biochemical bone
948 turnover markers and the associated ground reaction forces to high-impact exercise in
949 postmenopausal women. *Biol Sport.* 2020;37(1):41–8.
950 <https://doi.org/10.5114/biol sport.2020.91497>
- 951 60. Tosun A, Bölükbaşı N, Çingi E, Beyazova M, Ünlü M. Acute effects of a single session of
952 aerobic exercise with or without weight-lifting on bone turnover in healthy young women. *Mod*
953 *Rheumatol.* 2006;16(5):300–4. <https://doi.org/10.1007/s10165-006-0503-5>
- 954 61. Bowtell JL, Jackman SR, Scott S, Connolly LJ, Mohr M, Ermidis G, et al. Short duration small
955 sided football and to a lesser extent whole body vibration exercise induce acute changes in
956 markers of bone turnover. *Biomed Res Int.* 2016;2016:3574258.
957 <https://doi.org/10.1155/2016/3574258>
- 958 62. Smith C, Tacey A, Mesinovic J, Scott D, Lin X, Brennan-Speranza TC, Lewis JR, Duque G,
959 Levinger I. The effects of acute exercise on bone turnover markers in middle-aged and older
960 adults: A systematic review. *Bone.* 2021;143:115766.
961 <https://doi.org/10.1016/j.bone.2020.115766>
- 962 63. Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, et al. National Bone Health Alliance

963 Bone Turnover Marker Project: Current practices and the need for US harmonization,
964 standardization, and common reference ranges. *Osteoporos Int.* 2012;23(10):2425–33.
965 <https://doi.org/10.1007/s00198-012-2049-z>
966